Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Height-Growth Effect of Pegylated Recombinant Human Growth Hormone in Children with Different Genetic Height Backgrounds
ChiCTR2500107763Phase 4Not yet recruiting
- Sponsor
- The People's Hospital of Guang'an District
- Start
- Aug 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of peg-somatropin in growth disorder (2 cohorts), sponsored by The People's Hospital of Guang'an District. Primary endpoint: Change in height standard deviation score for chronological age (ΔHT SDS). Planned start Aug 2025; status: not yet recruiting.
02
Drugs
peg-somatropin
03
Conditions
growth disorder
Beyond the preview
Go deeper on ChiCTR2500107763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107763.